

Temsavir

Catalog No: tcsc0938



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

701213-36-7

Formula:

$C_{24}H_{23}N_7O_4$

Pathway:

Anti-infection

Target:

HIV

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 16.67 mg/mL (35.21 mM)

Alternative Names:

BMS-626529

Observed Molecular Weight:


473.48

Product Description

Temsavir (BMS-626529) is a novel attachment inhibitor that targets **HIV-1** gp120 and prevents its binding to CD4⁺ T cells.

IC₅₀ & Target: HIV-1^[1]

In Vitro: Temsavir has half-maximal effective concentration (EC₅₀) values of 50 against LAI virus of 0.7±0.4 nM. Temsavir exhibits an EC₅₀ of 0.01 nM against the most susceptible virus and an EC₅₀ of >2,000 nM against the least susceptible virus. The cytotoxicity profile of Temsavir is examined in several cell types from different human tissues. CC₅₀ values of >200 µM are observed in MT-2 (T lymphocytes), HEK293 (kidney), HEp-2 (larynx), HepG2 (liver), HeLa (cervix), HCT116 (colorectal), MCF-7 (breast), SK-N-MC (neuroepithelium), HOS (bone), H292 (lung), and MDBK (bovine kidney) cells measured after 3 or 6 days in culture. CC₅₀ values of 105 and 192 µM are obtained in the T-cell line PM1 and in PBMCs, respectively, following 6 days in culture. These results show that Temsavir exhibits low cytotoxicity in cell culture^[1]. Temsavir exhibits a broad spectrum of antiviral activity against a panel of clinical isolates, with a 50% inhibitory concentration (IC₅₀) ranging from subnanomolar levels to >0.1 µM^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!